BiotechTube

RO7049665

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Autoimmune Hepatitis

Conditions

Autoimmune Hepatitis, Autoimmune Chronic Hepatitis

Trial Timeline

Apr 19, 2021 → Nov 18, 2021

NCT ID
NCT04790916

About RO7049665

RO7049665 is a phase 2 stage product being developed by Roche for Autoimmune Hepatitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT04790916. Target conditions include Autoimmune Hepatitis, Autoimmune Chronic Hepatitis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04790916Phase 2Terminated

Competing Products

20 competing products in Autoimmune Hepatitis

See all competitors
ProductCompanyStageHype Score
SatralizumabChugai PharmaceuticalPhase 3
77
SHR0302 quick release tablets + SHR0302 sustained-release tabletsJiangsu Hengrui MedicinePhase 1
33
HR19042 Capsule, Tarpeyo®, Budenofalk®Jiangsu Hengrui MedicinePhase 1
33
HR19042 CapsulesJiangsu Hengrui MedicinePhase 2
52
Enteric-coated Mycophenolate SodiumNovartisPhase 3
77
Ianalumab + PlaceboNovartisPhase 3
77
VAY736NovartisPhase 2/3
65
remibrutinibNovartisPhase 1
33
rituximab (Mabthera®) + PlaceboRochePhase 3
77
NovoMix 30 + Tablet treatmentNovo NordiskPre-clinical
22
Anakinra 100Mg/0.67Ml Inj Syringe (Period 1) + Placebo injection (Period 1) + Anakinra 100Mg/0.67Ml Inj Syringe (Period 2) + Placebo injection (Period 2)Swedish Orphan BiovitrumPhase 2
51
branebrutinib + abatacept + branebrutinib placeboBristol Myers SquibbPhase 2
51
BMS-986165Bristol Myers SquibbPhase 1
32
NivolumabBristol Myers SquibbPhase 1
32
Fludarabine + Cyclophosphamide + TocilizumabBristol Myers SquibbPhase 1
32
BMS-986165 + RosuvastatinBristol Myers SquibbPhase 1
32
SAR445088SanofiPhase 1
32
BIVV020SanofiPhase 1
32
rilzabrutinibSanofiPhase 2
51
rilzabrutinib + placeboSanofiPhase 3
76

Other Products from Roche

EmicizumabApproved
85
rituximab + methotrexate + methylprednisolone + acetaminophen + antihistamineApproved
85
RituximabApproved
85
mycophenolate mofetil [CellCept]Approved
85
saquinavir/ritonavir + atazanavir/ritonavirApproved
85